Galmed Pharmaceuticals Ltd (GLMD) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Galmed Pharmaceuticals Ltd (GLMD) has a cash flow conversion efficiency ratio of -0.123x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.95 Million) by net assets ($15.78 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See debt-free asset ratio of Galmed Pharmaceuticals Ltd to measure how much of total assets are equity-financed.
Galmed Pharmaceuticals Ltd - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Galmed Pharmaceuticals Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore investment intensity of Galmed Pharmaceuticals Ltd to see how much of total assets are deployed in long-term investments.
Galmed Pharmaceuticals Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Galmed Pharmaceuticals Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Route1 Inc
V:ROI
|
-0.683x |
|
REY Resources Ltd
AU:REY
|
-0.165x |
|
ModivCare Inc
NASDAQ:MODV
|
0.937x |
|
Twin Vee Powercats Co
NASDAQ:VEEE
|
-0.096x |
|
Mountview Estates PLC
LSE:MTVW
|
0.060x |
|
Visible Gold Mines Inc
V:VGD
|
-0.072x |
|
Avricore Health Inc
V:AVCR
|
-0.761x |
|
Fragbite Group AB
ST:FRAG
|
-0.211x |
Annual Cash Flow Conversion Efficiency for Galmed Pharmaceuticals Ltd (2012–2025)
The table below shows the annual cash flow conversion efficiency of Galmed Pharmaceuticals Ltd from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Galmed Pharmaceuticals Ltd.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $15.78 Million | $-6.32 Million | -0.400x | -11.11% |
| 2024-12-31 | $16.33 Million | $-5.88 Million | -0.360x | +18.55% |
| 2023-12-31 | $13.88 Million | $-6.14 Million | -0.442x | +67.92% |
| 2022-12-31 | $13.42 Million | $-18.50 Million | -1.378x | -27.79% |
| 2021-12-31 | $30.50 Million | $-32.89 Million | -1.079x | -81.16% |
| 2020-12-31 | $44.15 Million | $-26.29 Million | -0.595x | -178.42% |
| 2019-12-31 | $69.85 Million | $-14.94 Million | -0.214x | -108.30% |
| 2018-12-31 | $87.89 Million | $-9.02 Million | -0.103x | +86.56% |
| 2017-12-31 | $15.79 Million | $-12.07 Million | -0.764x | +30.24% |
| 2016-12-31 | $11.07 Million | $-12.13 Million | -1.095x | -178.44% |
| 2015-12-31 | $21.55 Million | $-8.47 Million | -0.393x | -33.67% |
| 2014-12-31 | $31.41 Million | $-9.24 Million | -0.294x | -122.74% |
| 2013-12-31 | $-1.95 Million | $-2.52 Million | 1.294x | -16.85% |
| 2012-12-31 | $-1.98 Million | $-3.08 Million | 1.556x | -- |
About Galmed Pharmaceuticals Ltd
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases and related indications. The company develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in a Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have… Read more